177 related articles for article (PubMed ID: 35129069)
1. Feasibility and safety of targeting mitochondria for cancer therapy - preclinical characterization of gamitrinib, a first-in-class, mitochondriaL-targeted small molecule Hsp90 inhibitor.
Hayat U; Elliott GT; Olszanski AJ; Altieri DC
Cancer Biol Ther; 2022 Dec; 23(1):117-126. PubMed ID: 35129069
[TBL] [Abstract][Full Text] [Related]
2. Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease.
Kang BH; Tavecchio M; Goel HL; Hsieh CC; Garlick DS; Raskett CM; Lian JB; Stein GS; Languino LR; Altieri DC
Br J Cancer; 2011 Feb; 104(4):629-34. PubMed ID: 21285984
[TBL] [Abstract][Full Text] [Related]
3. Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer.
Kang BH; Siegelin MD; Plescia J; Raskett CM; Garlick DS; Dohi T; Lian JB; Stein GS; Languino LR; Altieri DC
Clin Cancer Res; 2010 Oct; 16(19):4779-88. PubMed ID: 20876793
[TBL] [Abstract][Full Text] [Related]
4. Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment.
Talaei S; Mellatyar H; Asadi A; Akbarzadeh A; Sheervalilou R; Zarghami N
Chem Biol Drug Des; 2019 May; 93(5):760-786. PubMed ID: 30697932
[TBL] [Abstract][Full Text] [Related]
5. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671
[TBL] [Abstract][Full Text] [Related]
6. Benzoquinone ansamycin 17AAG binds to mitochondrial voltage-dependent anion channel and inhibits cell invasion.
Xie Q; Wondergem R; Shen Y; Cavey G; Ke J; Thompson R; Bradley R; Daugherty-Holtrop J; Xu Y; Chen E; Omar H; Rosen N; Wenkert D; Xu HE; Vande Woude GF
Proc Natl Acad Sci U S A; 2011 Mar; 108(10):4105-10. PubMed ID: 21368131
[TBL] [Abstract][Full Text] [Related]
7. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.
Ying W; Du Z; Sun L; Foley KP; Proia DA; Blackman RK; Zhou D; Inoue T; Tatsuta N; Sang J; Ye S; Acquaviva J; Ogawa LS; Wada Y; Barsoum J; Koya K
Mol Cancer Ther; 2012 Feb; 11(2):475-84. PubMed ID: 22144665
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of the HSP90 molecular chaperone: current status.
Sharp S; Workman P
Adv Cancer Res; 2006; 95():323-48. PubMed ID: 16860662
[TBL] [Abstract][Full Text] [Related]
9. Tumor Necrosis Factor Receptor-associated Protein 1 (TRAP1) Mutation and TRAP1 Inhibitor Gamitrinib-triphenylphosphonium (G-TPP) Induce a Forkhead Box O (FOXO)-dependent Cell Protective Signal from Mitochondria.
Kim H; Yang J; Kim MJ; Choi S; Chung JR; Kim JM; Yoo YH; Chung J; Koh H
J Biol Chem; 2016 Jan; 291(4):1841-1853. PubMed ID: 26631731
[TBL] [Abstract][Full Text] [Related]
10. Novel Functional Role of Heat Shock Protein 90 in Mitochondrial Connexin 43-Mediated Hypoxic Postconditioning.
Tu RH; Li QJ; Huang Z; He Y; Meng JJ; Zheng HL; Zeng ZY; Zhong GQ
Cell Physiol Biochem; 2017; 44(3):982-997. PubMed ID: 29179175
[TBL] [Abstract][Full Text] [Related]
11. Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer.
Weber H; Valbuena JR; Barbhuiya MA; Stein S; Kunkel H; García P; Bizama C; Riquelme I; Espinoza JA; Kurtz SE; Tyner JW; Calderon JF; Corvalán AH; Grez M; Pandey A; Leal-Rojas P; Roa JC
Oncotarget; 2017 Apr; 8(16):26169-26184. PubMed ID: 28412732
[TBL] [Abstract][Full Text] [Related]
12. Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors.
Saif MW; Erlichman C; Dragovich T; Mendelson D; Toft D; Burrows F; Storgard C; Von Hoff D
Cancer Chemother Pharmacol; 2013 May; 71(5):1345-55. PubMed ID: 23564374
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
Ohba S; Hirose Y; Yoshida K; Yazaki T; Kawase T
J Neurosurg; 2010 Jan; 112(1):33-42. PubMed ID: 19408974
[TBL] [Abstract][Full Text] [Related]
14. Discovery of diamine-linked 17-aroylamido-17-demethoxygeldanamycins as potent Hsp90 inhibitors.
Li Z; Jia L; Wang J; Wu X; Hao H; Wu Y; Xu H; Wang Z; Shi G; Lu C; Shen Y
Eur J Med Chem; 2014 Nov; 87():346-63. PubMed ID: 25277067
[TBL] [Abstract][Full Text] [Related]
15. P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response.
McCollum AK; TenEyck CJ; Stensgard B; Morlan BW; Ballman KV; Jenkins RB; Toft DO; Erlichman C
Cancer Res; 2008 Sep; 68(18):7419-27. PubMed ID: 18794130
[TBL] [Abstract][Full Text] [Related]
16. Non-Benzoquinone Geldanamycin Analog, WK-88-1, Induces Apoptosis in Human Breast Cancer Cell Lines.
Zhao YR; Li HM; Zhu M; Li J; Ma T; Huo Q; Hong YS; Wu CZ
J Microbiol Biotechnol; 2018 Apr; 28(4):542-550. PubMed ID: 29618179
[TBL] [Abstract][Full Text] [Related]
17. Sulforaphane potentiates the efficacy of 17-allylamino 17-demethoxygeldanamycin against pancreatic cancer through enhanced abrogation of Hsp90 chaperone function.
Li Y; Zhang T; Schwartz SJ; Sun D
Nutr Cancer; 2011; 63(7):1151-9. PubMed ID: 21875325
[TBL] [Abstract][Full Text] [Related]
18. The heat-shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin suppresses glial inflammatory responses and ameliorates experimental autoimmune encephalomyelitis.
Dello Russo C; Polak PE; Mercado PR; Spagnolo A; Sharp A; Murphy P; Kamal A; Burrows FJ; Fritz LC; Feinstein DL
J Neurochem; 2006 Dec; 99(5):1351-62. PubMed ID: 17064348
[TBL] [Abstract][Full Text] [Related]
19. 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models.
Burger AM; Fiebig HH; Stinson SF; Sausville EA
Anticancer Drugs; 2004 Apr; 15(4):377-87. PubMed ID: 15057143
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the mitochondrial Hsp90 chaperone network: a novel, efficient treatment strategy for cancer?
Siegelin MD
Cancer Lett; 2013 Jun; 333(2):133-46. PubMed ID: 23376257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
